Navigation Links
Man's best friend: Common canine virus may lead to new vaccines for deadly human diseases
Date:11/27/2012

Athens, Ga. Researchers at the University of Georgia have discovered that a virus commonly found in dogs may serve as the foundation for the next great breakthrough in human vaccine development.

Although harmless in humans, parainfluenza virus 5, or PIV5, is thought to contribute to upper respiratory infections in dogs, and it is a common target for canine vaccines designed to prevent kennel cough. In a paper published recently in PLOS ONE, researchers describe how this virus could be used in humans to protect against diseases that have eluded vaccine efforts for decades.

"We can use this virus as a vector for all kinds of pathogens that are difficult to vaccinate against," said Biao He, the study's principal investigator and professor of infectious diseases in UGA's College of Veterinary Medicine. "We have developed a very strong H5N1 flu vaccine with this technique, but we are also working on vaccines for HIV, tuberculosis and malaria."

PIV5 does not cause disease in humans, as our immune system is able to recognize and destroy it. By placing antigens from other viruses or parasites inside PIV5, it effectively becomes a delivery vehicle that exposes the human immune system to important pathogens and allows it to create the antibodies that will protect against future infection.

This approach not only ensures full exposure to the vaccine but also is much safer because it does not require the use of attenuated, or weakened, pathogens. For example, an HIV vaccine delivered by PIV5 would contain only those parts of the HIV virus necessary to create immunity, making it impossible to contract the disease from the vaccine.

"Safety is always our number one concern," said He, who is also a Georgia Research Alliance distinguished investigator and member of the Faculty of Infectious Diseases. "PIV5 makes it much easier to vaccinate without having to use live pathogens."

Using viruses as a delivery mechanism for vaccines is not a new technique, but previous efforts have been fraught with difficulty. If humans or animals already possess a strong immunity to the virus used for delivery, the vaccine is unlikely to work, as it will be destroyed by the immune system too quickly.

"Pre-existing immunity to viruses is the main reason most of these vaccines fail," He said.

But in this latest study, He and his colleagues demonstrate that immunity to PIV5 does not limit its effectiveness as a vaccine delivery mechanism, even though many animalsincluding humans already carry antibodies against it.

In their experiments, the researchers found that a single dose inoculation using PIV5 protected mice from the influenza strain that causes seasonal flu. Another single dose experimental vaccine also protected mice from the highly pathogenic and deadly H5N1 virus commonly known as bird flu.

This recent work is a culmination of more than fifteen years of research and experimentation with the PIV5 virus, and He has confidence that it will serve as an excellent foundation for vaccines to treat diseases in both animals and humans.

"I believe we have the best H5N1 vaccine candidate in existence," He said. "But we have also opened up a big field for a host of new vaccines."


'/>"/>

Contact: Biao He
bhe@uga.edu
706-542-2855
University of Georgia
Source:Eurekalert

Related medicine news :

1. Gut Bacteria Often Similar in Humans, Chimps: Study
2. First trial in humans of minicells: A completely new way of delivering anti-cancer drugs
3. Testing pain killers on humans could save money and speed the arrival of new drugs
4. Lust May Dampen Humans Sense of Disgust, Study Suggests
5. Ancient Genome Appears to Have Links to Modern Humans
6. More clues about why chimps and humans are genetically different
7. New insights into why humans are more susceptible to cancer and other diseases
8. First evidence from humans on how alcohol may boost risk of cancer
9. New Seal Flu Could Pose Threat to Humans
10. Humans Might Be Hard-Wired to Love Thy Neighbor
11. Dogs May Mourn as Deeply as Humans Do
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... California (PRWEB) , ... January 17, 2017 , ... ... have a point of difference. Eden Activewear is a stand-out company for several ... are exclusively online and only manufacture on demand, this is called 'Agile' manufacturing ...
(Date:1/17/2017)... ... , ... Kevin Harrington (one of the original Sharks from mega-hit reality series ... topic of Beauty and Personal Care. , Everyone makes New Year’s ... commit to these changes than beginning with personal care and beauty products? AsSeenOnTV.pro will ...
(Date:1/17/2017)... Lehi, Utah (PRWEB) , ... January 17, 2017 ... ... provider of accredited, online continuing education for EMS and firefighting professionals, has released ... Training (VILT) Solution. These new courses are taught live in an online classroom ...
(Date:1/17/2017)... ... ... Neil H. Greco Insurance Agency, a northern New Jersey firm that provides ... a charity drive to raise awareness of heart disease and promote habits that improve ... is responsible for 1 in every 4 deaths at the national level each year. ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... breast cancer survivor Sandra Lee as keynote speaker for the 34th Annual Miami ... , In making the announcement, PER® president, Phil Talamo, said, “We are delighted ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017 Paragon Bioservices ... provide product development services for a variety of ... (NIAID) medical product development activities. The IDIQ ... contractor pool for task order awards up to ... leader in manufacturing and process development of biopharmaceuticals, ...
(Date:1/17/2017)... -- Management to Discuss Acquisition of ... KIT-302 Development On Track For An NDA Submission ... Q1 2017   ... Ltd. (NASDAQ: KTOV ; TASE: KTOV), an innovative biopharmaceutical company, announced ... at 8:30am Eastern Time to discuss the recent acquisition of a majority ...
(Date:1/17/2017)... DUBLIN , Jan. 17, 2017  Jazz Pharmaceuticals ... first patient has been enrolled in a Phase 3 ... versus best supportive care (BSC) in the prevention of ... undergoing hematopoietic stem cell transplant (HSCT) who are at ... VOD.  The defibrotide clinical trial will be conducted across ...
Breaking Medicine Technology: